Document is current
Any future updates will be listed below
-
Authors
Sanchez-Escamilla, Miriam
Flynn, Jessica
Devlin, Sean
Maloy, Molly
Fatmi, Samira A.
Tomas, Ana Alarcon https://orcid.org/0000-0002-6290-1061
Escribano-Serrat, Silvia
Ponce, Doris https://orcid.org/0000-0002-9422-5766
Sauter, Craig S.
Giralt, Sergio A. https://orcid.org/0000-0003-1944-5053
Scordo, Michael
Perales, Miguel-Angel https://orcid.org/0000-0002-5910-4571
- License Information
-
More Information
Article History
Received: 11 May 2022
Revised: 5 January 2023
Accepted: 13 January 2023
First Online: 31 January 2023
Competing interests
: MAP reports honoraria from Abbvie, Allovir, Astellas, Bristol-Myers Squibb, Celgene, Equilium, Exevir, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Novartis, Nektar Therapeutics, Omeros, OrcaBio, Takeda, and VectivBio AG, Vor Biopharma. He serves on DSMBs for Cidara Therapeutics, Medigene, Sellas Life Sciences, and Servier, and the scientific advisory board of NexImmune. He has ownership interests in NexImmune and Omeros. He has received institutional research support for clinical trials from Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. MS served as a paid consultant for McKinsey & Company, Angiocrine Bioscience, Inc., and Omeros Corporation; received research funding from Angiocrine Bioscience, Inc., and Omeros Corporation; served on ad hoc advisory boards for Kite – A Gilead Company; and received honoraria from i3Health and Medscape for CME-related activity. The other authors declare no competing interests.
